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Serum c-reactive protein levels predict 
neurological outcome after aneurysmal 
subarachnoid hemorrhage
O nível sérico da proteína C-reativa como fator preditivo do prognóstico neurológico após 
hemorragia subaracnóidea aneurismática
Flávio Ramalho Romero1, Eduardo de Freitas Bertolini2, Eberval G. Figueiredo3, Manoel Jacobsen Teixeira4
Cerebral vasospasm is the major cause of delayed morbid-
ity and mortality following aneurysmal subarachnoid hemor-
rhage (aSAH). Despite recent advances in the management 
of patients with ruptured cerebral aneurysms, case fatality 
rates remain high (35 to 50%)1-3. More than 40% of survivors 
experience long-term cognitive and functional limitations1,3-5. 
Although approximately two-thirds of patients with aneurys-
mal SAH develop angiographic vasospasm, only half of this 
group will develop a delayed neurological deficit1,3,6-9.
Experimental and clinical evidence suggests that inter-
cellular adhesion molecule-1 (ICAM-1) mediating leukocyte 
migration may play a crucial role in the pathogenesis of 
cerebral vasospasm9-13. SAH increases endothelial ICAM-1 
expression1,3-5,14,15 and the resultant perivascular leukocyte 
migration1,3-5,9,16,17. Furthermore, serum ICAM-1 levels corre-
late with the onset of cerebral vasospasm1,3,6-9. Perivascular 
chemokine-activated inflammatory cells synthesize and re-
lease endothelin-1, a potent vasoconstrictor, as well as su-
peroxide free radicals, thus leading to inactivation of nitric 
oxide (NO) and vasoconstriction1,3,6-9,14,15. Anti-ICAM-1 anti-
bodies decrease leukocyte migration and attenuate cerebral 
vasospasm after SAH1,3,6-9.
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aBStract
Objectives: Our aim was to evaluate the relationship between serum C-reactive protein (CRP) levels and the neurological prognosis and 
development of vasospasm in patients with aneurysmal subarachnoid hemorrhage (aSAH). Methods: Eighty-two adult patients with aSAH 
diagnoses were prospectively evaluated. Glasgow Coma Scale (GCS) score, Hunt and Hess grade, Fisher grade, cranial CT scans, digital sub-
traction angiography studies and daily neurological examinations were recorded. Serial serum CRP measurements were obtained daily be-
tween admission and the tenth day. Glasgow Outcome Scale (GOS) and the modified Rankin Scale (mRS) were used to assess the prognosis. 
Results: Serum CRP levels were related to severity of aSAH. Patients with lower GCS scores and higher Hunt and Hess and Fisher grades 
presented statistically significant higher serum CRP levels. Patients with higher serum CRP levels had a less favorable prognosis. Conclu-
sions: Increased serum CRP levels were strongly associated with worse clinical prognosis in this study. 
Key words: C-reactive protein, subarachnoid hemorrhage, vasospasm, intracranial aneurysm.
reSUMO
Objetivos: Nosso propósito foi avaliar a relação entre os níveis séricos de proteína C-reativa (PCR), o prognóstico neurológico e o desenvolvi-
mento de vasoespasmo em pacientes com hemorragia subaracnóidea aneurismática (HSAa). Métodos: Foram avaliados prospectivamente 
82 pacientes adultos com diagnóstico de HSAa. Foram anotados em prontuário: a escala de coma de Glasgow (ECG), a escala de Hunt-Hess, 
a escala de Fisher, TC de crânio, angiografia cerebral e o exame neurológico diário. Foi determinada diariamente a PCR sérica, da admissão ao 
décimo dia. Foi utilizadas a escala de resultados de Glasgow e a escala de Rankin modificada (mRS) para avaliar o prognóstico. Resultados: 
Os níveis séricos de PCR estavam relacionados à severidade da HSAa. Pacientes com EGC baixos e altos graus pelas escalas de Hunt-Hess e 
Fisher tiveram níveis de PCR séricos estatisticamente elevados. Pacientes com altos níveis de PCR séricos tiveram prognóstico menos favo-
rável. Conclusões: Aumentos dos níveis séricos da PCR foram fortemente associados com pior prognóstico clínico neste estudo.
Palavras-Chave: proteína C-reativa, hemorragia subaracnóidea, vasoespasmo, aneurisma intracraniano.
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Identifying risk factors may improve clinical predic-
tion and allow for more effective treatment of vasospasm. 
Measurement of sensitive inflammatory markers, such as 
C-reactive protein (CRP), significantly increases the ability to 
make accurate predictions and prevent or appropriately treat 
coronary thrombotic events8,18,19. Previous clinical studies 
have shown that elevated levels of high-sensitivity CRP could 
predict the development of coronary vasospasm8,9. Berk et al.8 
found that elevated CRP was associated with increased risk 
of a subsequent myocardial infarction. Interest in inflamma-
tory markers for cerebral vasospasm has increased, particu-
larly when related to neurological outcomes.
In this study, we measured serum CRP levels in patients 
with aSAH and analyzed the relationships between systemic 
CRP levels and the severity of aSAH.
MethOdS
Between May 2006 and May 2010, 82 adult patients were 
selected for a prospective cohort study at Hospital Ipiranga/
SUS in São Paulo. The inclusion criteria were as follows: 1) di-
agnosis of aSAH and cerebral aneurysms established by a CT 
scan and four-vessel DS angiography study; 2) patient age >18 
years; 3) patient admission to our institutions within the first 
24 hours postictus. The exclusion criteria were concomitant or 
recent acute myocardial infarction, recent surgery (≤30 days) 
prior to the event, and/or clinical or laboratory evidence of 
chronic systemic infection. In addition, patients who died be-
fore completing 10 days of treatment were not included.
Patient demographics, clinical status on admission 
Glasgow Coma Scale (GCS) (GCS scores and Hunt and Hess 
grades), head CT scans, severity of the SAH blood clot load 
(Fisher grades), location of a ruptured aneurysm (standard 
four-vessel DS angiography) and neurological examinations 
on admission and daily thereafter were recorded. Surgical 
clipping was performed in 56 (68.2%) of the 82 patients for 
70 (76.1%) of the 92 aneurysms, whereas endovascular treat-
ment was used in 26 patients (31.7%) for 22 (23.9%) of the 
92 aneurysms. The selection of surgical versus endovascular 
treatment was based on criteria, such as the anatomical loca-
tion of the lesion, the size and morphological features of the 
aneurysm, the presence of multiple aneurysms, the presence 
of a mass effect caused by the aneurysm and/or an associ-
ated hematoma, and the patient’s neurological and general 
medical condition and preference.
The serum CRP levels were measured daily between ad-
mission and the tenth day, and the measurements obtained 
were recorded. The patients’ clinical outcome was evaluat-
ed using the Glasgow Outcome Scale (GOS) and modified 
Rankin Scale (mRS) at discharge from our institutions. This 
study was approved by the local Ethics Committee. Statistical 
analyses were performed using SAS version 9.1.3.
reSUltS
The admission GCS scores ranged from 3 to 15 (mean=12). 
Hunt and Hess scores on admission ranged from I to V 
(mean=2.5), and Fisher grades from 1 to 4 (mean=1.5). The 
GOS scores on discharge ranged from 2 to 5 (mean=4.0), and 
the range of mRS scores was from 0 to 5 (mean=1.3). 
A progressive increase in CRP levels from admission to 
the third day post ictus was observed, followed by a slow de-
crease until the ninth day (Fig 1). Patients with lower GCS 
scores presented increased CRP measurements (correla-
tion coefficient methodology; z=−8.912, p<0.0001, r=−0.89) 
(Fig 2). Low admission GCS scores were significantly in-
versely correlated with high serum CRP values. Likewise, 
patients with higher Hunt and Hess grades on admission 
developed significantly higher serum CRP levels (correla-
tion coefficient methodology; z=6.467, p<0.0001, r=0.82). 
Similarly, patients with higher Fisher grades on admission 
showed increased levels of CRP (correlation coefficient 
methodology; z=7.652, p<0.0001, r=0.86)
There was no statistically significant difference in serum 
CRP levels between the group of patients undergoing surgi-
cal clipping and those undergoing endovascular coil occlu-
sion. With regard to their GOS scores, patients with high-
er serum CRP levels (correlation coefficient methodology; 
z=−6.181, p<0.0001, r=−0.81) (Fig 3) presented less favorable 
outcomes. A statistically significant inverse correlation was 
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Fig 1. Schematic representation of summated measured serum 
CRP levels of our patients. CRP: C-reactive protein. 
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Fig 2. Schematic representation of serum CRP levels with 
regard to the GCS score at admission. CRP: C-reactive protein; 
GCS: Glasgow Coma Scale.
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established in our series between serum CRP levels and GOS 
scores. A similar statistically strong relationship was found 
between mRS scores on discharge and CRP measurements 
(correlation coefficient methodology; z=6.762, p<0.0001, 
r=0.82). Occurrences of vasospasm were significantly cor-
related with higher CRP levels (Fig 4). 
diScUSSiOn
Delayed cerebral vasospasm is associated with high 
rates of morbidity and mortality. Several inflammatory 
mechanisms are directly involved in the pathogenesis of 
cerebral vasospasm, with increased levels of various sol-
uble adhesion molecules (such as E-selectin, intercellular 
adhesion molecule-1 and vascular adhesion molecule-1) 
and cytokines (such as IL-6 and IL-1) that have been de-
tected in the plasma and CSF of patients with aSAH3,6-9. 
CRP is a sensitive inflammatory marker, with synthe-
sis in hepatocytes. It is strongly stimulated by interleukin-
61-3,6,7,20-23. Additionally, IL-1, which has been implicated in 
the pathogenesis of cerebral vasospasm, also provides a 
strong stimulus for CRP synthesis1,3-5. Therefore, elevat-
ed CRP concentrations may well be associated with an 
increased possibility of developing cerebral vasospasm 
and subsequently a delayed ischemic neurological deficit 
(DIND)1,3,24-29. 
There was a strong inverse correlation between ad-
mitting GCS scores and serum CRP levels on admission 
(r=−0.89 and r=−0.82, respectively). Hunt and Hess and 
Fisher grades were also correlated in a statistically signif-
icant fashion with the CRP measurements in our cohort. 
These data clearly indicate that CRP levels significantly 
correlate with the severity of aSAH and with occurrences 
of vasospasm. Furthermore, the elevated CRP levels were 
associated with worse clinical outcome, as expressed in 
GOS and mRS scores. Additionally, we found no statis-
tically significant differences in occurrences of angio-
graphic vasospasm between patients undergoing surgi-
cal treatment and those undergoing endovascular coil 
occlusion. 
Our strict inclusion criteria minimized the influence 
of other confounding factors, such as systemic infection 
or concomitant systemic conditions, and hence the sta-
tistical analysis defining the influence of CRP levels on 
vasospasm occurrences and neurological final outcomes 
is compelling. Unfortunately, the clinical significance 
of elevated serum CRP measurements in patients with 
aSAH is confounded by the fact that most of these pa-
tients may have other concomitant systemic infections 
or pathological conditions that could potentially result 
in increased serum CRP concentrations. Additionally, the 
surgical manipulation in these patients could influence 
the systemic CRP levels. 
It is well known that the clinical outcome among pa-
tients with aSAH depends on many factors. The system-
ic association between CRP levels and clinical outcomes 
may well be influenced by other parameters in a complex 
and frequently unpredictable way. In addition, CRP is a 
sensitive but nonspecific inflammatory marker. A large-
scale, multicenter, prospective clinical study is necessary 
to validate our results and to determine the role of serum 
CRP in identifying patients who are at high risk of devel-
oping cerebral vasospasm.
In conclusion, this prospective clinical study demon-
strated that the clinical and radiologic severity of aSAH 
correlated significantly with serum CRP levels, since pa-
tients with low GCS scores and high Hunt and Hess 
and Fisher grades presented elevated serum CRP levels. 
Additionally, CRP levels were able to predict occurrences 
of vasospasm and poor clinical outcomes in a statistically 
significant fashion. Routine use of CRP levels may identify 
patients who are at high risk of developing cerebral vasos-
pasm and may have a positive impact on therapeutic strat-
egies and the future management of patients with aSAH.
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Fig 4. Schematic representation of serum C-reactive protein 
levels in patients with and without vasospasm.
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Fig 3. Schematic representation of serum CRP measurements in 
patients with GOS score ≥4 versus patients with GOS score <4 at 
discharge. CRP: C-reactive protein; GOS: Glasgow Outcome Scale.
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